doxorubicin final chemotherapy project 12 9 2014
TRANSCRIPT
Intravenous Admixture and Sterile Compounding
PHM1270 - M223
Angela Busbee
December 16, 2014
Doxorubicin Trade name: Adriamycin, Rubex
Chemotherapy drug class: antitumor antibiotics
One of the most powerful chemotherapy drugs invented that is used to treat a wide variety of cancers
FDA approved for use alone or in combination with other drugs
US approval: 1974
Doxorubicin Treats the following cancers:
Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
Breast Cancer (adjuvant therapy when it has spread to lymph nodes after surgery
Gastric cancer
Hodgkin lymphoma
Neuroblastoma
Non-hodgkin lymphoma
Ovarian cancer
Doxorubicin Treats the following cancers:
Small cell lung cancer
Soft tissue and bone sarcomas
Thyroid cancer
Transitional cell bladder cancer
Wilms tumor
Researched for treatment of other types cancer.
Doxorubicin Dosage forms and strengths of doxorubicin hydrochloride:
Vials clear red solution
10 mg/5 mL, 20 mg/10 mL, 50 mg/25 mL, 150 mg/75 mL, and 200 mg/100 mL
Vials red-orange lyophilized powder
10 mg, 20 mg, 50 mg, and 150 mg
Storage
Refrigerated 2° to 8°C (36° to 46°F)
Protect from light
Retain in carton until used
Discard unused portion
Doxorubicin Therapy routine for Breast Cancer, ovary, prostate,
stomach, thyroid; small cell cancer of lung, liver; squamous cell cancer of head and neck; multiple myeloma, Hodgkin's disease, lymphomas, ALL, AML
60-75 mg/m² IV q21Days OR
60 mg/m² IV q14Days OR
40-60 mg/m² IV q21-28Days OR
20 mg/m²/dose qweek
Doxorubicin Limit lifetime cumulative dose to <550 mg/m² to
reduce risk of cardio toxicity (congestive heart failure & cardiomyopathy)
Monitor: CBC, cardiac function, LFTs (liver function tests)
Doxorubicin Is it an effective treatment?
Considered largely as the drug of choice for first-line therapy of metastatic breast cancer
Response rates of 29% to 43% with median survival rate of 2 years
Reason to use docetaxel and doxorubicin for metastatic breast cancer is that there is a partial clinical cross-resistance between the two drugs.
Doxorubicin Phase 1 trial of doxorubicin followed by docetaxel is a
very active combination with overall response rate of 90% in the highest feasible dose without G-CSF support
Doxorubicin Data on secondary cancers after breast cancer cure
rate:
Patients taking drug rate of second cancers at:
10 years was 3.8%
15 years was 7%
Doxorubicin Side effects:
Nausea or vomiting
Pain at injection site
Temporary Low blood counts of white & red blood cells and platelets
Mouth sores
Alopecia (hair loss on scalp or body)
Eyes watering (first week of treatment)
Urine color red, red-brown, orange, or pink in first 1-2 days after dose administered
Doxorubicin First two weeks of taking drug:
Nail beds darken
Skin darkens where previous radiation treatment was administered
Fertility issues
Serious: can cause issue with pumping of heart that may occur 7-8 years after treatment.
Lifetime limit on amount patients may receive.
Doxorubicin Precautions while taking:
Aspirin and their products should not be taken without physician approval
No vaccinations without physician approval
Use contraceptives (barrier type recommended -condoms) & do not get pregnant
Do not breast feed
Not to be taken by patients with congestive heart failure, if you have already taken high doses of this drug, or have bone marrow suppression or other blood count issues
Doxorubicin Administered:
IV Push (syringe) in not less than 3 to 5 minutes
IVPB (IV admixture) over 15 to 60 minutes
Must not be given via intramuscular or subcutaneous route
Doxorubicin
The End
Bibliography doxorubicin (Rx) Adriamycin, Caelyx, Rubex. (1994 - 2014). Retrieved from
Medscape: http://reference.medscape.com/drug/doxorubicin-342120 Doxorubicin Cancer Treatment. (2014). Retrieved from CancerTreatment.net:
http://doxorubicin.cancertreatment.net/ Doxorubicin Hydrochloride. (2014, 09 17). Retrieved from National Cancer
Institute at the National Institutes of Health: http://www.cancer.gov/cancertopics/druginfo/doxorubicinhydrochloride
Diéras, M. V. (1997, 08 01). Review of Docetaxel/Doxorubicin Combination in Metastatic Breast Cancer - See more at: http://www.cancernetwork.com/review-article/review-docetaxeldoxorubicin-combination-metastatic-breast-cancer#sthash.o4sOCNSV.dpuf. Retrieved from cancerNetwork.com: http://www.cancernetwork.com/review-article/review-docetaxeldoxorubicin-combination-metastatic-breast-cancer
Doxorubicin. (n.d.). Retrieved from Chemocare.com: http://chemocare.com/chemotherapy/drug-info/doxorubicin.aspx#.VIS15tLF9e8
Bibliography Laboratories, B. (2014, 02). HIGHLIGHTS OF PRESCRIBING INFORMATION.
Retrieved from Adriamycin - Boehringer Ingelheim: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Ben+Venue_Bedford+Labs/55390-237-01+ADR+50MG/5539023701
McAuley, P. D. (2012, 05 02). Drug: Doxorubicin HCL - Adriamycin®. Retrieved from GLOBALRPh.com: http://www.globalrph.com/doxorubicin.htm#DOSAGE_AND_ADMINISTRATION
Secondary Malignancies. (n.d.). Retrieved from CancerConnection.com: http://news.cancerconnect.com/secondary-malignancies/
Woolston, M. C. (n.d.). Chemotherapy and Side Effects. Retrieved from HealthDay News for Healthier Living: http://consumer.healthday.com/encyclopedia/cancer-8/mis-cancer-news-102/chemotherapy-and-side-effects-648006.html